Skip to main content

Advertisement

Log in

Administration of insulin glargine thrice weekly by medical staff at a dialysis unit: a new insulin regimen for diabetic management in physically impaired patients undergoing hemodialysis

  • Original article
  • Published:
Diabetology International Aims and scope Submit manuscript

Abstract

Diabetic patients undergoing hemodialysis may have difficulty in self-injecting insulin due to physical impairment or other disabilities. We hypothesized that postdialysis administration of insulin glargine by medical staff would improve diabetes care in this high-risk patient group. In this report, we describe six hemodialysis patients with type 2 diabetes and inadequate glycemic control who were admitted to our hospital. All patients had an inability to self-inject insulin due to visual impairment and/or stroke symptoms. Therefore, they had been unable to receive insulin treatment at the outpatient dialysis clinics within the last few months. After admission, the patients were administered insulin glargine after each hemodialysis session, thrice-weekly. Regarding glycemic control, blood glucose profiles including the circadian variation of 13-point blood glucose values for 48 h, hemoglobin A1C (HbA1C), and glycated albumin (GA) were evaluated before and after insulin treatment. Post-dialysis administration of insulin glargine significantly reduced blood glucose levels, particularly during the first 24 h after injection. HbA1C and GA levels were significantly decreased after 6 months, with no increase in the incidence of severe hypoglycemic episodes. Although further large controlled studies are needed, post-dialysis administration of insulin glargine by medical staff may improve glycemic control in physically impaired diabetic patients undergoing hemodialysis at outpatient clinics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1a–g

Similar content being viewed by others

References

  1. Oomichi T, Emoto M, Tabata T, et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care. 2006;29:1496–500.

    Article  PubMed  Google Scholar 

  2. Kalantar-Zadeh K, Kopple JD, Regidor DL, et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care. 2007;30:1049–55.

    Article  PubMed  Google Scholar 

  3. Hayashino Y, Fukuhara S, Akiba T, et al. Diabetes, glycaemic control and mortality risk in patients on haemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study. Diabetologia. 2007;50:1170–7.

    Article  PubMed  CAS  Google Scholar 

  4. Iglesias P, Díez JJ. Insulin therapy in renal disease. Diabetes Obes Metab. 2008;20:811–23.

    Article  Google Scholar 

  5. Bilous RW. End-stage renal failure and management of diabetes. Diabet Med. 2004;21(Suppl 1):12–4.

    Article  PubMed  Google Scholar 

  6. Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis. 2007;50:865–79.

    Article  PubMed  CAS  Google Scholar 

  7. Inaba M, Okuno S, Kumeda Y, Osaka CKD Expert Research Group, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol. 2007;18:896–903.

    Article  PubMed  CAS  Google Scholar 

  8. Stumvoll M. Glucose production by the human kidney—its importance has been underestimated. Nephrol Dial Transpl. 1998;13:2996–9.

    Article  CAS  Google Scholar 

  9. Seino Y, Nanjo K, Tajima N, et al. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. Diabetol Int. 2010;1:2–20.

    Google Scholar 

  10. Abe M, Okada K, Matsumoto K. Plasma insulin and C-peptide concentrations in diabetic patients undergoing hemodialysis: comparison with five types of high-flux dialyzer membranes. Diabetes Res Clin Pract. 2008;82:e17–9.

    Article  PubMed  CAS  Google Scholar 

  11. Collier RO Jr, Baker FB. Some Monte Carlo results on the power of the F-test under permutation in the simple randomized block design. Biometrika. 1966;53:199–203.

    PubMed  Google Scholar 

  12. Owens DR, Coates PA, Luzio SD, et al. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care. 2000;23:813–9.

    Article  PubMed  CAS  Google Scholar 

  13. Tascona DJ, Morton AR, Toffelmire EB, et al. Adequacy of glycemic control in hemodialysis patients with diabetes. Diabetes Care. 2006;29:2247–51.

    Article  PubMed  Google Scholar 

  14. DeFronzo RA, Alvestrand A, Smith D, et al. Insulin resistance in uremia. J Clin Invest. 1981;67:563–8.

    Article  PubMed  CAS  Google Scholar 

  15. Heinemann L, Woodworth J. Pharmacokinetics and glucodynamics of insulin lispro. Drugs Today. 1998;34:23–36.

    CAS  Google Scholar 

  16. Jacovsen LV, Popescu G, Plum A. Pharmacokinetics of insulin detemir in subjects with renal or hepatic impairment. Diabetologia. 2002;45(Suppl 1):A259.

    Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tetsuya Babazono.

About this article

Cite this article

Bouchi, R., Babazono, T., Onuki, T. et al. Administration of insulin glargine thrice weekly by medical staff at a dialysis unit: a new insulin regimen for diabetic management in physically impaired patients undergoing hemodialysis. Diabetol Int 2, 197–201 (2011). https://doi.org/10.1007/s13340-011-0044-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13340-011-0044-9

Keywords

Navigation